Study of the effect of Serenoa Repens on prostatic inflammation
Does treatment with Serenoa Repens results in improvement of inflammation score compared to no treatment, in men with histologically prostatic inflammation?
Prof. Stavros Gravas
100 participants
Jul 20, 2012
Interventional
Conditions
Summary
The aim of the study is to determine the effect of Serenoa Repens use on prostatic inflammation, based on histological and immunohistochemical criteria. Patients with prostatic inflammation based on biopsy results are randomized to receive either Serenoa Repens 320mg/d (Group 1) or no treatment (Group 2). Patients will receive a second biopsy 6 months later. Inflammation score and immunohistochemical results, with or without treatment with Serenoa Repens, will be statistically compared, so as to evaluate the effect on the prostatic inflammation.
Eligibility
Inclusion Criteria1
- Patients with proven inflammation in prostatic biopsy
Exclusion Criteria5
- Patients who have been already treated for LUTS with herbal medication.
- Patients who have been diagnosed with prostate cancer at the first biopsy.
- Patients who underwent pelvic radiotherapy for any reason.
- Patients with a permanent urethral catheter.
- Patient with a previous TURP or intravesical instillations due to bladder cancer.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients with prostatic inflammation based on biopsy result are randomized to receive either Serenoa Repens (oral capsules for 6 months) 320mg daily (Group 1) or no treatment (Group 2). Monitoring will be based on patients' tablet return.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12613000888763